Biogen wins U.S. approval of long acting multiple sclerosis drug

August 15, 2014 11:34 PM

16 0

NEW YORK (Reuters) - U.S. health regulators on Friday approved Biogen Idec Inc's Plegridy, a long-acting multiple sclerosis drug that the company expects will eventually replace its older big-selling Avonex treatment.

The company received European approval on July 23 for the drug that is intended to reduce relapses of the debilitating disease and slow its progression.

Also read: Global Gas Producers Turn to Next Challenge: Finding Buyers

Read more

To category page